Dosing equation for tacrolimus using genetic variants and clinical factors
Open accessThe DOI matches its Crossref record.
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Patients with low tacrolimus troughs are at a higher risk of rejection while those with high troughs are at an increased risk for toxicity. Therefore, achieving the therapeutic range is important. • CYP3A5 genotype and days post transplant have been previously shown individually to be associated with tacrolimus troughs. WHAT THIS STUDY ADDS • This paper presents the first dosing model for tacrolimus using a combination of genetic and clinical factors in adult kidney transplant recipients. It was developed from one of the largest tacrolimus pharmacogenetic studies conducted to date (681 subjects and 11 823 trough concentrations). • We found that CL/F was significantly influenced by days post transplant, CYP3A5 genotype, transplantation at a steroid sparing centre, recipient age and the use of a calcium channel blocker. • Our large sample size enabled us to define the distinct differences in tacrolimus CL/F between three CYP3A5 genotype groups (*1/*1, *1/*3 and *3/*3). • This study is an important step towards using pharmacogenetic information in the clinical setting. AIM To develop a dosing equation for tacrolimus, using genetic and clinical factors from a large cohort of kidney transplant recipients. Clinical factors and six genetic variants were screened for importance towards tacrolimus clearance (CL/F). METHODS Clinical data, tacrolimus troughs and corresponding doses were collected from 681 kidney transplant recipients in a multicentre observational study in the USA and Canada for the first 6 months post transplant. The patients were genotyped for 2 724 single nucleotide polymorphisms using a customized Affymetrix SNP chip. Clinical factors and the most important SNPs (rs776746, rs12114000, rs3734354, rs4926, rs3135506 and rs2608555) were analysed for their influence on tacrolimus CL/F. RESULTS The CYP3A5*1 genotype, days post transplant, age, transplant at a steroid sparing centre and calcium channel blocker (CCB) use significantly influenced tacrolimus CL/F. The final model describing CL/F(l h−1) was: 38.4 ×[(0.86, if days 6–10) or (0.71, if days 11–180)]×[(1.69, if CYP3A5*1/*3 genotype) or (2.00, if CYP3A5*1/*1 genotype)]× (0.70, if receiving a transplant at a steroid sparing centre) × ([age in years/50]−0.4) × (0.94, if CCB is present). The dose to achieve the desired trough is then prospectively determined using the individuals CL/F estimate. CONCLUSIONS The CYP3A5*1 genotype and four clinical factors were important for tacrolimus CL/F. An individualized dose is easily determined from the predicted CL/F. This study is important towards individualization of dosing in the clinical setting and may increase the number of patients achieving the target concentration. This equation requires validation in an independent cohort of kidney transplant recipients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation
Lee, J. R., Muthukumar, T., Dadhania, D., Taur, Y., Jenq, R. R., Toussaint, N. C., Ling, L., Pamer, E., & Suthanthiran, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122399 · Cited by 211
Tang, J., Liu, R., Zhang, Y.-L., Liu, M.-Z., Hu, Y.-F., Shao, M.-J., Zhu, L.-J., Xin, H.-W., Feng, G.-W., Shang, W.-J., et al. (2017) · Scientific Reports · doi:10.1038/srep42192 · Cited by 154
Andrews, L. M., Li, Y., De Winter, B. C. M., Shi, Y.-Y., Baan, C. C., Van Gelder, T., & Hesselink, D. A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1395413 · Cited by 142
Thishya, K., Vattam, K. K., Naushad, S. M., Raju, S. B., & Kutala, V. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191921 · Cited by 65
Jang, H. Y., Song, J., Kim, J. H., Lee, H., Kim, I.-W., Moon, B., & Oh, J. M. (2022) · npj Digital Medicine · doi:10.1038/s41746-022-00639-0 · Cited by 63
“Various clinical conditions have also been reported to affect tacrolimus PK, such as concomitant drugs, genotypes (e.g., SNPs), diet, and clinical values 63,64 .”
Background
Metadata
- Authors
- Passey, C., Birnbaum, A. K., Brundage, R. C., Oetting, W. S., Israni, A. K., & Jacobson, P. A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2011-11-09
- Volume
- 72
- Issue
- 6
- Pages
- 948-957
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2166801934
- Cited by
- 169
- References
- 0
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dosing equation for tacrolimus using genetic variants and clinical factors. https://app.cochat.ai/papers/10.1111/j.1365-2125.2011.04039.x
- The paper
- Passey, C., Birnbaum, A. K., Brundage, R. C., Oetting, W. S., Israni, A. K., & Jacobson, P. A. (2011). Dosing equation for tacrolimus using genetic variants and clinical factors. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2011.04039.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.